OSTX — OS Therapies Incorporated
$1.250.00%
Last close: · regular session
Last 60 sessions
Opening the full analysis uses 1 of your 3 free tickers today.
Chart, dilution, float and news for OSTX in the TickerWise workspace.
OS Therapies Incorporated, a clinical stage biopharmaceutical company, focuses on the identification, development, and commercialization of treatments for osteosarcoma and other solid tumors in the United States. Its pipeline includes OST-HER2, an off-the-shelf immunotherapy for osteosarcoma patients; and OST-tunable drug conjugate (OST-tADC), an antibody-drug conjugate (ADC) silicone dioxide linker technology, with a plug-and-play platform that features tunable pH sensitive silicone linkers. OS Therapies Incorporated was incorporated in 2018 and is based in Grasonville, Maryland.
Company profile
- Sector: Healthcare
- Industry: Biotechnology
- Country: US
- Exchange: New York Stock Exchange Arca
- Employees: 4
- Website: https://ostherapies.com
Latest SEC filings for OSTX
Latest OSTX news
- Rubenstein Public Relations Named Agency of Record for OS Therapies Read article
- OS Therapies Reports Significant Three-Year Survival Data for Bone Cancer Treatment Read article
- OS Therapies Achieves Statistically Significant Final Three-Year Overall Survival Benefit for Herlystic(TM)-Treated Patients in Phase 2b Pulmonary Metastatic Osteosarcoma Trial Read article
- OS Therapies appoints Kerry Clem as CCO, Frank Knuettel II as CFO Read article
- OS Therapies Appoints Kerry Clem as Chief Commercial Officer and Frank Knuettel II as Chief Financial Officer Read article
Opening the full analysis uses 1 of your 3 free tickers today.
Educational tool only — not investment advice.